Full-Time

Associate Product Manager

Fertility Solutions

Cooper Companies

Cooper Companies

201-500 employees

Global medical devices and vision care

Compensation Overview

$70k - $80k/yr

Trumbull, CT, USA + 1 more

More locations: Livingston, NJ, USA

In Person

On-site in Trumbull, CT or Livingston, NJ; travel up to 10–15% per year may be required.

Bachelor's, Master's

Category
Product (1)
Required Skills
Market Research
Supply Chain Management
Product Management
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Cooper Companies

See people who can refer or advise you

Requirements
  • The candidate must be analytical, structured, comfortable working with complex information from multiple sources, and able to manage multiple concurrent tasks in a fast-paced environment.
  • The candidate must have business curiosity and an interest in science, fertility, in vitro fertilization customers, laboratory workflows, medical devices, and global healthcare markets.
  • The candidate must be detail-oriented, highly organized, proactive, willing to take ownership of tasks, and able to drive follow-up and create structure when processes or data are incomplete.
  • The candidate must be able to gather, organize, analyze, and clearly communicate business, market, product, pricing, and portfolio data.
  • The candidate must have strong communication, presentation, interpersonal, networking, and collaborative abilities, and be able to coordinate stakeholders and follow up on actions, decisions, and deliverables.
  • The candidate must be able to create PowerPoint presentations, dashboards, summaries, and business analyses in Excel.
  • The candidate must be fluent in spoken and written English.
  • The candidate must have 2 to 4 years of experience in product management, marketing, business analysis, market research, commercial excellence, sales support, medical devices, diagnostics, life sciences, laboratory equipment, or a related field.
  • The candidate must have a Bachelor’s or Master’s degree in Business Administration, Marketing, Science, Engineering, Life Sciences, or a related field.
Responsibilities
  • Lead portfolio operations processes, including stock-keeping unit rationalization, registration tracking, portfolio health monitoring, lifecycle tracking, and business performance reporting.
  • Coordinate intake, prioritization, and tracking of sustaining engineering requests, product improvement initiatives, and cross-functional portfolio actions with Product Management and key stakeholders.
  • Develop and maintain portfolio insights and decision-support tools covering competitive intelligence, pricing analysis, installed-base analytics, market trends, customer feedback, and performance dashboards.
  • Provide data-driven recommendations for portfolio decisions, commercial planning, lifecycle management, and product category strategy.
  • Coordinate cross-functional input from Supply Chain, Operations, Service, Finance, Regulatory, Quality, regional commercial teams, and Product Management to ensure portfolio analyses, business cases, and recommendations are complete, accurate, and decision-ready.
  • Coordinate the development, approval, and deployment of product communications, sales enablement tools, launch materials, training content, portfolio documentation, and other commercial assets.
  • Establish and maintain Product Management processes, reporting tools, governance mechanisms, and operating cadences to improve portfolio visibility, prioritization, decision-making, and cross-functional alignment.
  • Facilitate recurring regional, product, and cross-functional portfolio review forums and ensure that risks, opportunities, actions, decisions, and follow-up activities are communicated and tracked.
Desired Qualifications
  • Knowledge of in vitro fertilization, fertility, embryology, laboratory workflows, medical devices, laboratory equipment, or software-enabled devices.
  • Experience supporting portfolio management, business analysis, pricing analysis, competitive intelligence, product launches, lifecycle management, or commercial planning.
  • Experience coordinating cross-functional projects, recurring business processes, dashboards, reporting tools, or stakeholder review forums.
  • Experience working with global or cross-functional teams.

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

1958

Get referred to Cooper Companies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Management kept CooperSurgical and expanded buybacks to $3 billion on September 9, 2026.
  • MiSight grew 20% and MyDay posted double-digit growth in fiscal Q3 2026.
  • Free cash flow hit $273 million quarterly, supporting deleveraging and repurchases.

What critics are saying

  • U.S. channel destocking cut CooperVision Q3 revenue to $717 million and hits Q4.
  • CooperSurgical faces Miudella competition after Organon's February 2026 licensing deal.
  • Accrued litigation liability reached $316.5 million in July 2026, threatening cash and multiples.

What makes Cooper Companies unique

  • CooperVision leads premium daily lenses; MyDay, MiSight, and torics drove 2026 growth.
  • CooperSurgical owns ParaGard, the only U.S. non-hormonal copper IUD franchise.
  • Global scale across 130 countries and 15,000 employees supports resilient distribution and R&D.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Performance Bonus

Health Insurance

401(k) Retirement Plan

Life Insurance

Wellness Program

Professional Development Budget

Company News

Yahoo Finance
Sep 14th, 2026
Cooper Companies cuts 2026 forecast as contact lens demand weakens, CooperVision revenue drops to $717M

The Cooper Companies cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected contact lens demand affected its CooperVision business. The company now expects adjusted earnings of $4.51–$4.55 per share, down from $4.58–$4.66, whilst revenue guidance was reduced to $4.23–$4.25 billion from $4.29–$4.32 billion. Third-quarter revenue came in at $1.07 billion, below Wall Street's $1.10 billion estimate. CooperVision revenue fell to $717 million, with management citing US channel inventory reductions that are expected to continue affecting the fourth quarter. The company completed its strategic review and decided to retain CooperSurgical rather than sell the business. Despite the challenges, Cooper increased its share-repurchase authorisation from $2 billion to $3 billion.

Yahoo Finance
Sep 10th, 2026
Cooper Companies Q3 earnings beat estimates at $1.15, revenues miss at $1.07B on US destocking

The Cooper Companies reported third-quarter fiscal 2026 adjusted earnings per share of $1.15, beating the Zacks Consensus Estimate of $1.11 by 3.6%. However, revenues of $1.066 billion missed estimates of $1.099 billion by 3.0%, impacted by US channel inventory reductions in its CooperVision segment. Shares fell 15.9% in after-hours trading following the announcement. The stock has declined 22.5% year-to-date, contrasting with the S&P 500's 11% gain. CooperVision revenues remained flat year over year at $717 million, pressured by inventory destocking. CooperSurgical grew 2% to $349.2 million. MiSight delivered 20% organic growth, whilst MyDay products recorded double-digit growth across multiple categories.

Yahoo Finance
Sep 9th, 2026
Cooper Companies reports $271.8M record quarterly free cash flow, retains CooperSurgical after strategic review

Cooper Companies reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1%, with non-GAAP earnings per share rising 4% to $1.15. The company generated record quarterly free cash flow of $273 million, bringing year-to-date free cash flow to $528 million, up 86% year over year. CooperVision revenue remained flat at $717 million due to planned US channel inventory reductions, though underlying consumer demand continued growing at mid-single digits. CooperSurgical posted 3% organic growth, with fertility revenue increasing 5% to $141 million. The board concluded its strategic review and decided to retain CooperSurgical, whilst authorising an additional $1 billion in share repurchases. For the fourth quarter, Cooper expects flat to 2% organic revenue growth and non-GAAP EPS of $1.05 to $1.09.

Yahoo Finance
Sep 9th, 2026
CooperCompanies reports $1.08B Q1 revenue, up 7.9% year-on-year, beating estimates by 2.7%

CooperCompanies reported first-quarter revenues of $1.08 billion, up 7.9% year-on-year and exceeding analyst expectations by 2.7%. The medical device manufacturer, which focuses on vision care contact lenses and women's health products, also beat earnings per share estimates. The result came as the medical devices and supplies sector reported a strong quarter overall. Five tracked companies in the diversified category beat consensus revenue estimates by 2.9% on average, though next quarter's guidance came in 2.2% below expectations. Despite delivering the weakest full-year guidance update in the group, CooperCompanies' shares have risen 9% since reporting. The stock currently trades at $67.62.

Yahoo Finance
Sep 9th, 2026
CooperCompanies misses Q2 revenue estimates by 2.9%, cuts full-year guidance, stock drops 16.8%

CooperCompanies reported second-quarter revenue of $1.07 billion, missing analyst estimates of $1.10 billion. The medical device company's sales were flat year-on-year, whilst its operating margin improved to 20.8% from 16.6% in the same quarter last year. The company lowered its full-year revenue guidance to $4.24 billion at the midpoint, down from $4.30 billion, representing a 1.5% decrease. Adjusted earnings per share guidance was also reduced to $4.53 at the midpoint, a 1.9% decrease. Despite beating analyst expectations with adjusted EPS of $1.15 versus estimates of $1.12, the company's shares fell 16.8% following the announcement. CEO Al White cited reduced US channel inventory at CooperVision as weighing on results. CooperCompanies develops medical devices for vision care and women's health.